May 22, 2019
Panel 1 – Emerging Transformative Initiatives
- APOL1 and the NIH-APOLLO Study – Barry I. Freedman, MD, FACP, Chief of Nephrology, Wake Forest School of Medicine
- Kidney Health Initiative, How FDA & ASN Convened a New Era of Collaboration – Zachary Cahill, Marketing and Communications Specialist, Kidney Health Initiative
- Leveraging Ingenuity: KidneyX and the Drive to Disrupt Kidney Care Status Quo – Rachel Meyer, Director, Policy and Government Affairs, American Society of Nephrology
Panel 2- Disrupting Disease Progression
- Potential Opportunities to Disrupt CKD Progression: Insights from the CRIC Study – Harold I. Feldman, MD, MSCE, Professor of Medicine & Epidemiology, University of Pennsylvania
- Understanding the Factors That Impact Patients Outside the Dialysis Center – Barry Smith, PhD, MD, President/CEO The Rogosin Institute
- Transforming Kidney Care by Going Upstream – Doug Johnson, MD, Vice Chairman, Dialysis Clinic, Inc.
- Exciting Developments and Challenges in Diagnosing and Treating Glomerular Diseases – Jerry B. Appel, PhD, MD, Co-Director, Clinical Nephrology, New York Presbyterian
Panel 3 – Clinical Trials Reinvented: Remote Technologies & Reduced Patient Burden
- Randomized Controlled Trials in Nephrology: Last Year and the Next 5 Years – Michael Walsh, PhD, MD, Associate Professor, McMaster University
- CTTI Recommendations for Engaging Patients as Partners – Petros Okubagzi, MD, Assistant Vice President, Research Operations MedStar Health
- Advocacy Group Engagement Matters: To Patients, To Industry, To the Future of Drug Development – Courtney Firak, MPH, Director Advocacy Relations, Continuum Clinical
- The Power of Capacities: AAKP Center for Research & Education and the AAKP Center for Patient Engagement and Advocacy – Diana Clynes, AAKP Executive Director
Panel 4 – Evolutions in Transplantation
- Transplantations & Kidney Patients: New Developments, Greater Hope – John S. Gill, MD, MS, University of British Columbia, President, American Society of Transplantation
- Transplantation in Highly-Sensitized Patients: The Unmet Need – Eric Litjens, PhD, Senior Director Global Commercial Operations, Head of Patient Advocacy and Global Marketing, Hansa Medical
- Transplant Precision Medicine: The Potential of Measuring Kidney Function and Fluid Status – Joe Muldoon, CEO, FAST BioMedical
- Blood Tests that Measure Graft Rejection – Reginald Seeto, MB.BS, President, Chief Business Officer, CareDX
Panel 5- Improving Status Quo: Dialysis
- Incorporating Dialysis into Life(and not vice versa) – Rebecca Schmidt, DO, FACP, FASN, Professor and Chief, Dept. of Medicine, West Virginia University
- The Potential of Bioengineered Vessels to Impact Future for Dialysis Patients – Juliana Blum, PhD, Co-Founder, Humacyte
- Redefining Dialysis Patient Comprehensive Care – Ikenna Okezie, MD, MBA, CEO, Somatus Inc.
May 23, 2019
Panel 6 – Back to the Future: Home, Wearable, Implantable Therapies
- How is FDA Supporting Medical Device Innovation? – Carolyn Neuland, PhD, Renal Devices Branch, Division of Reproductive, Gastro-Renal & Urological Devices, U.S Food & Drug Administration
- Making Home Hemodialysis a Mainstream Dialysis Modality – Bruce Culleton, MD, Vice President, Chief Medical Officer, CVS Health
- Biohybrid Device for Implantable Renal Replacement Therapy – Shuvo Roy, PhD, University of California San Francisco
- Mobility and Patient Freedom: Wearable Kidney Therapies- Victor Gura, MD, Cedars Sinai Medical Center
Panel 7 – Government Age of Change
- Kidney Precision Medicine Project: Why We Need Precision Medicine in Nephrology – Robert Star, MD, Director, Division of Kidney, Urological, & Hematologic Disease, National Institute of Diabetes & Digestive & Kidney Diseases, National Institute of Health
- Drug Development for Kidney Diseases: A Regulatory Perspective – Aliza Thompson, MD, MS, Clinical Team Leader, Division of Cardiovascular & Renal Products, Center for Drug Evaluation & Research, U.S. Food & Drug Administration
- Congress and Congressional Process: A Positive Force for Patients & Research Advancement – Peggy Tighe, Principal, Government Relations & Legislative Affairs, Powers Law
Panel 8 – Nephrology: New Scientific Explorations
- An Update on Hypertension Management – George Bakris, MD, Professor of Medicine, Director Comprehensive Hypertension Center
- Innovations in the Treatment of CKD-Related Anemia: Focus on Improving Patient-Centered Outcomes – Jim Sloand, MD, FACP, FASN, Senior Medical Affairs Leader, Global Medical Affairs, Cardiovascular Renal Metabolic, AstraZeneca
- Stem Cell Therapy in Diabetic Kidney Disease – Sabyasachi Sen, MD, FRCP, FACP, FACE, The George Washington University
Panel 9 – Patient Power Unleashed
- Living with a Rare Kidney Disease: Accelerating a Treatment After a 30-Year Search – Richard Nelson, Founder, Rare Kidney Disease Foundation
- Unleashing the Power of Patients and Health Professionals to Reassert the Value of Nephrology – Tod Ibrahim, Executive Vice President, American Society of Nephrology
